Recent Quotes (30 days)

You have no recent quotes
chg | %

Valeant Pharmaceuticals Intl Inc  

(Public, TSE:VRX)   Watch this stock  
Find more results for VRX
134.45
+0.80 (0.60%)
Apr 17 - Close
TSE data delayed by 15 mins - Disclaimer
Currency in CAD
Range 132.13 - 135.77
52 week 72.59 - 170.45
Open 133.65
Vol / Avg. 250,064.00/422,371.00
Mkt cap 44.83B
P/E     -
Div/yield     -
EPS -2.86
Shares 333.41M
Beta 0.21
Inst. own 85%
May 5, 2014
Q1 2014 Valeant Pharmaceuticals International, Inc. Earnings Release (Estimated) Add to calendar
Feb 27, 2014
Q4 2013 Valeant Pharmaceuticals International, Inc. Earnings Release
Feb 27, 2014
Q4 2013 Valeant Pharmaceuticals International, Inc. Earnings Conference Call
  

Key stats and ratios

Q4 (Dec '13) 2013
Net profit margin 6.06% -14.97%
Operating margin 9.11% -8.22%
EBITD margin - 39.96%
Return on average assets 1.78% -3.76%
Return on average equity 9.86% -19.60%
Employees 17,200 -
CDP Score - -

Address

2150 ST. ELZEAR BLVD. WEST
LAVAL, QC H7L 4A8
Canada
+1-514-7446792 (Phone)

Website links

Description

Valeant Pharmaceuticals International, Inc., formerly Biovail Corporation, is a multinational, specialty pharmaceutical company that develops, manufactures and markets a range of pharmaceutical products. The Company operates in five business segments: U.S. Neurology and Other, U.S. Dermatology, Canada and Australia, Branded Generics - Europe and Branded Generics -Latin America. Within its U.S. Dermatology segment and Branded Generic - Europe segment the Company generates service revenue from contract services in the areas of dermatology and topical medication. On December 12, 2011, it acquired assets of the Ortho Dermatologics division of Janssen Pharmaceuticals, Inc. (Janssen). In August 2013, Valeant Pharmaceuticals International Inc completed the acquisition of Bausch + Lomb Holdings Incorporated. In January 2014, the Company's wholly-owned subsidiary Valeant Pharmaceuticals International acquired Solta Medical Inc.